Abstract: The present invention relates to a method for the treatment of acute myeloid leukemia (AML) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of the presently-described formula (I) or a salt, solvate or prodrug thereof. Specific compounds of the invention include 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran which is also known as BNC105 and disodium 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate which is also known as BNC105P.

Abstract: A process is provided to produce water that will meet the specifications of the United States Pharmacopeia Inc. for Purified Water and Water for Injection, and water for dialysis as circumscribed by the American Association for Advancement of Medical Instrumentation (AAMI). The system has no storage tanks where stagnant water will be fouled by biofilm colonizing the tank surface. Water is circulated throughout the purification system and drawn as required, on demand. The water is purified and used immediately or recycled and repurified to ensure quality. Sanitation of the purification system, maintaining microbiological purity and cleaning is done by controlling the pH so that it is normally acidic by maintaining a high carbon dioxide concentration in solution, the carbon dioxide being allowed to pass into the permeate from a reverse osmosis membrane assembly used to purify the water.